Nutriband Advances Abuse-Deterrent Fentanyl Patch with FDA Submission
Event summary
- Nutriband has selected a commercial brand name for its abuse-deterrent fentanyl transdermal system and will submit it to the FDA for approval.
- The company partnered with Brand Institute, a leader in pharmaceutical brand name development, for the naming and identity development.
- The product leverages Nutriband’s AVERSA™ technology, aiming to be the first abuse-deterrent fentanyl patch.
- Peak annual US sales are projected between $80 million and $200 million, with global market potential.
The big picture
Nutriband’s submission of its abuse-deterrent fentanyl patch for FDA approval marks a critical step in addressing the global unmet need for safe pain management. The partnership with Brand Institute underscores the strategic importance of proprietary branding in the pharmaceutical industry, particularly for products targeting abuse deterrence. With projected peak sales of $80 million to $200 million in the US alone, the product’s success could significantly impact Nutriband’s market position and financial performance.
What we're watching
- Regulatory Approval
- The pace at which the FDA and other international regulatory agencies review and approve the proposed brand name and product labeling.
- Market Penetration
- Whether Nutriband can successfully launch and scale the product in the US and expand into global markets.
- Competitive Positioning
- How the abuse-deterrent technology will differentiate the product in a competitive pain management market.
Related topics